Clinical observation of trimetazidine in patients with congestive heart failure

Objective To observe the effects of trimetazidine on cardiac function in patients with chronic heart failure (CHF). Methods Eighty patients with CHF received conventional therapy were randomly divided into 2 groups, the trimetazidine group (n=40) and the conventional therapy group (n=40). Patients in the trimetazidine group were given trimetazidine 20 mg three times a day for 6 months. NYHA functional class and echocardiographic indices(LVEDD, LVMI, LVEF) were compared before and after 6 months therapy. Results After 6 months of therapy, cardiac function was improved in 95% CHF patients with trimetazidine therapy, while only 52. 5% in conventional group; LVMI in trimetazidine group[(106. 7±13.6) g/m~2 vs. (136. 7±14. 8) g/m~2]was lower than in conventional group LVEF was higher in trimetazidine group[(51.4±6.9) % vs. (43.6±7.7) %]than in conventional group. Conclusions Trimetazidine can improve cardiac function in CHF patients treated with conventional therapy.